Cereno Scientific – new board member proposed to strengthen competence within strategy and financing
Cereno Scientific today announced that Rein Piir is proposed as a new board member to the company’s Board. Rein’s experience in strategy, financing and investor relations will contribute to broadened competence in the company’s Board. A decision on the election of a new board member will be made at the company's annual general meeting on June 9, 2021.
“Cereno faces exciting and important challenges with both the Phase II clinical program and two preclinical programs in cardiovascular disease. We look forward to taking part of Rein's long experience of strategy and financing work, with a broad network in the Nordic region and the US, and believe that he will make a significant contribution to Cereno's further company development,” says Catharina Bäärnhielm, Chair of the Board at Cereno Scientific.
“It will be fun to work with Cereno, a company with strong roots and knowledge of the development of new concepts for the treatment of cardiovascular diseases. The company is at an exciting stage, both the clinical and the preclinical projects will show the continued way forward for the company's development. I look forward to being able to contribute my experiences to support a continued positive development for Cereno,” says Rein Piir.
Rein Piir, born in 1958, has many years of experience in business and acquisition analysis, capital market matters, investor relations and alliance management towards global companies. He also provides advice to listed life science companies in business planning, strategy development, financing, and transactions. Previously, he has been Head of Analysis at Carnegie Investment Bank, CFO/Head of Investor Relations at listed Medivir and auditor at PricewaterhouseCoopers. Ongoing Board assignments include IRLAB Sweden.
The annual general meeting (AGM) will be held exclusively digitally, with the support of the temporary rules that apply during the current covid-19 pandemic. Participation in the AGM will take place by using a digital postal voting form. Notice and other documents related to the AGM on June 9, 2021 will be available on the company's website no later than three weeks prior.
For further information, please contact:
Catharina Bäärnhielm
Email: catharina.baarnhielm@cerenoscientific.com
Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. A clinical phase II study for CS1 in PAH is expected to be initiated in September 2021 under its US FDA granted orphan drug designation (ODD) status. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.